Other TRβ agonists, including resmetirom, ALG-055009, MB07811 (VK-2809), TG68, and HSK31679 [349], show potential for treating DED, DR, and AMD by modulating oxidative stress, apoptosis, and inflammatory signaling in retinal cells. Here, THRB is linked to age-related macular degeneration.